Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NTRK1 fusion Entrectinib vaginal carcinoma sensitive detail...
NTRK2 fusion Entrectinib vaginal carcinoma sensitive detail...
NTRK2 fusion Larotrectinib vaginal carcinoma sensitive detail...
NTRK1 fusion Larotrectinib vaginal carcinoma sensitive detail...
RET fusion Selpercatinib vaginal carcinoma sensitive detail...
MLH1 negative Pembrolizumab vaginal carcinoma sensitive detail...
MSH6 negative Pembrolizumab vaginal carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03345784 Phase I Adavosertib + Cisplatin WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer Terminated USA | CAN 0
NCT03418480 Phase Ib/II BNT113 HPV Anti-CD40 RNA Vaccine (HARE-40) Completed GBR 0